German drug maker Boehringer Ingelheim announced on Friday that it had stopped work on a pill for low libido in women, or a ‘female Viagra’ drug as it’s commonly called. Our involved writing about this drug takes a middle-of-the road analysis to the research results.
We don’t embrace Leonore Tiefer’s unyielding stance on the pursuit of a female version of Viagra: “The discontinuation of clinical research on flibanserin represents a victory for the F.D.A. and the public, and the latest travesty in the decade-long hunt for a so-called ‘pink Viagra’. The agency asked for more data on safety and efficacy and the company responded that they lack the resources for such research. This confirms that Boehringer-Ingelheim was always more invested in marketing than science.” via NYTimes
Boehringer’s Uniquely American Results